A Phase Ib Clinical Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2004 Injection in Patients With Atrial Fibrillation
Latest Information Update: 04 Mar 2024
At a glance
- Drugs SHR-2004 (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions
- Sponsors Beijing Suncadia Pharmaceuticals
Most Recent Events
- 04 Mar 2024 New trial record